Maple Securities USA’s Novartis NVS Stock Holding History

Maple Securities USA’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-19,562	Closed	-$1.72M	–	137
2015 Q2	$1.72M	Buy	+19,562	New	+$1.79M	0.16%	48
2014 Q4	–	Sell	-5,529	Closed	-$466K	–	231
2014 Q3	$466K	Buy	+5,529	New	+$447K	0.05%	141
2013 Q3	–	Sell	-4,628	Closed	-$293K	–	487
2013 Q2	$293K	Buy	+4,628	New	+$301K	0.03%	342

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Maple Securities USA's NVS Position: Q3 2015 in Review

Maple Securities USA sold out of Novartis (NVS) in Q3 2015, closing a stake of 19,562 shares — an estimated $1.72M sold.

Maple Securities USA first reported a position in NVS in Q2 2013 and held it in 3 quarters. The position peaked at $1.72M in Q2 2015. 925 funds tracked by Wall St. Rank hold NVS as of Q3 2015.

Maple Securities USA reported no remaining Novartis position as of Q3 2015 after selling out during the quarter.
Maple Securities USA sold 19,562 Novartis shares in Q3 2015, an estimated $1.72M.
Maple Securities USA first reported a position in Novartis in Q2 2013 and held it in 3 quarters.
Maple Securities USA's Novartis position peaked at $1.72M in Q2 2015.
925 funds tracked by Wall St. Rank held Novartis as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.